7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Vestibulocochlear Nerve Diseases D000160 1 associated lipids
Acromegaly D000172 6 associated lipids
Actinobacillus Infections D000189 4 associated lipids
Actinomycosis D000196 2 associated lipids
Addison Disease D000224 3 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Hyperplasia, Congenital D000312 2 associated lipids
Albuminuria D000419 18 associated lipids
Alzheimer Disease D000544 76 associated lipids
Angina, Unstable D000789 14 associated lipids
Angioid Streaks D000793 1 associated lipids
Ankylosis D000844 1 associated lipids
Aortic Diseases D001018 11 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Rheumatoid D001172 3 associated lipids
Arthropathy, Neurogenic D001177 1 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Biliary Atresia D001656 4 associated lipids
Body Weight D001835 333 associated lipids
Bone Diseases, Developmental D001848 2 associated lipids
Bone Diseases, Endocrine D001849 1 associated lipids
Bone Diseases, Metabolic D001851 9 associated lipids
Bone Neoplasms D001859 5 associated lipids
Bone Resorption D001862 7 associated lipids
Cachexia D002100 21 associated lipids
Calcinosis D002114 5 associated lipids
Carcinoid Heart Disease D002275 1 associated lipids
Carcinoma D002277 18 associated lipids
Carcinoma, Non-Small-Cell Lung D002289 72 associated lipids
Carcinoma, Papillary D002291 3 associated lipids
Carcinosarcoma D002296 7 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Celiac Disease D002446 16 associated lipids
Brain Ischemia D002545 89 associated lipids
Cherubism D002636 1 associated lipids
Chondroblastoma D002804 1 associated lipids
Chondrocalcinosis D002805 1 associated lipids
Chronic Disease D002908 7 associated lipids
Cleidocranial Dysplasia D002973 1 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Coronary Disease D003327 70 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptosporidiosis D003457 3 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Dengue D003715 2 associated lipids
Dental Occlusion, Traumatic D003769 1 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dental Pulp Exposure D003789 1 associated lipids
Dental Pulp Necrosis D003790 6 associated lipids
Dentin Dysplasia D003805 1 associated lipids
Dermatomyositis D003882 2 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Angiopathies D003925 20 associated lipids
Diabetic Nephropathies D003928 39 associated lipids
Diabetic Neuropathies D003929 5 associated lipids
Diarrhea D003967 32 associated lipids
Dilatation, Pathologic D004108 5 associated lipids
Disease Susceptibility D004198 12 associated lipids
Emphysema D004646 1 associated lipids
Encephalitis D004660 15 associated lipids
Endocrine System Diseases D004700 4 associated lipids
Endometriosis D004715 29 associated lipids
Eye Neoplasms D005134 2 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Foreign-Body Reaction D005549 10 associated lipids
Gingival Recession D005889 2 associated lipids
Glioma D005910 112 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Graves Disease D006111 6 associated lipids
Heart Failure D006333 36 associated lipids
Heart Valve Diseases D006349 4 associated lipids
Hemarthrosis D006395 1 associated lipids
Hematoma, Subdural D006408 3 associated lipids
Hemophilia A D006467 10 associated lipids
Hepatitis C D006526 7 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hip Dislocation D006617 1 associated lipids
Hip Fractures D006620 2 associated lipids
Hirsutism D006628 3 associated lipids
Histiocytosis, Langerhans-Cell D006646 1 associated lipids
HIV Seropositivity D006679 15 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypercalcemia D006934 13 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperinsulinism D006946 27 associated lipids
Hyperparathyroidism D006961 3 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hypertension D006973 115 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Hypocalcemia D006996 12 associated lipids
Hypothyroidism D007037 32 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Bolon B et al. Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. 2002 Arthritis Rheum. pmid:12483715
Golmia RP et al. Increased osteoprotegerin and decreased pyridinoline levels in patients with ankylosing spondylitis: comment on the article by Gratacós et al. 2002 Arthritis Rheum. pmid:12483748
Toraldo G et al. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. 2003 Proc. Natl. Acad. Sci. U.S.A. pmid:12490655
Choi BK et al. Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. 2003 Infect. Immun. pmid:12496170
Bengtsson AK and Ryan EJ Immune function of the decoy receptor osteoprotegerin. 2002 Crit. Rev. Immunol. pmid:12498383
Chagraoui H et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. 2003 Blood pmid:12506018
Lee Y et al. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. 2003 J. Orthop. Res. pmid:12507581
Sabokbar A et al. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. 2003 J. Orthop. Res. pmid:12507582
Elhasid R et al. Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. 2003 Am. J. Hematol. pmid:12508266
Haynes DR et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. 2003 Rheumatology (Oxford) pmid:12509625
Takayanagi H [Cross-talk between immune and skeletal systems]. 2002 Nippon Rinsho pmid:12510352
Spyrou P et al. Cytokine release by osteoblast-like cells cultured on implant discs of varying alloy compositions. 2002 Clin Oral Implants Res pmid:12519337
Berenson JR Advances in the biology and treatment of myeloma bone disease. 2002 Semin. Oncol. pmid:12520479
Woo KM et al. Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones. 2002 Exp. Mol. Med. pmid:12526098
Kanematsu M et al. [Effects of gravity on the gene expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor]. 1999 Biol. Sci. Space pmid:12532992
Katavić V et al. Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. 2003 J. Immunol. pmid:12538719
Clohisy D Cellular mechanisms of osteolysis. 2003 J Bone Joint Surg Am pmid:12540662
Vanderkerken K et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. 2003 Cancer Res. pmid:12543775
Kato I et al. TRANCE together with IL-7 induces pre-B cells to proliferate. 2003 Eur. J. Immunol. pmid:12548564
Sordillo EM and Pearse RN RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. 2003 Cancer pmid:12548579
Oyajobi BO and Mundy GR Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. 2003 Cancer pmid:12548580
Croucher PI et al. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. 2003 Cancer pmid:12548581
Lipton A Bisphosphonates and metastatic breast carcinoma. 2003 Cancer pmid:12548585
Demers LM Bone markers in the management of patients with skeletal metastases. 2003 Cancer pmid:12548589
Body JJ et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. 2003 Cancer pmid:12548591
Kanematsu M et al. [Clinostat rotation culture modulates gene expression of osteoclastogenesis-regulating factors via a cyclic-AMP dependent mechanism]. 2000 Biol. Sci. Space pmid:12561872
Buckley KA and Fraser WD Receptor activator for nuclear factor kappaB ligand and osteoprotegerin: regulators of bone physiology and immune responses/potential therapeutic agents and biochemical markers. 2002 Ann. Clin. Biochem. pmid:12564836
Xing L et al. Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. 2003 J. Bone Miner. Res. pmid:12568403
Cao J et al. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. 2003 J. Bone Miner. Res. pmid:12568404
Johnson-Pais TL et al. Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. 2003 J. Bone Miner. Res. pmid:12568416
Clohisy JC et al. RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. 2003 J. Orthop. Res. pmid:12568950
Yu Q et al. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. 2003 J. Immunol. pmid:12574344
Rifas L et al. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts. 2003 J. Cell. Biochem. pmid:12577299
Gordeladze JO and Reseland JE A unified model for the action of leptin on bone turnover. 2003 J. Cell. Biochem. pmid:12577304
Fahrleitner A et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. 2003 Bone pmid:12584041
Lanzi R et al. GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. 2003 Eur. J. Endocrinol. pmid:12590637
Lubberts E et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. 2003 J. Immunol. pmid:12594294
Stajszczyk M [Role of receptor activator of nuclear factor kappa B (RANK), its ligand (RANK-L) and osteoprotegerin (OPG) in bone metabolism]. 2002 Pol. Arch. Med. Wewn. pmid:12600190
Fahrleitner A et al. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status. 2002 Wien. Klin. Wochenschr. pmid:12602117
Shipman CM and Croucher PI Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. 2003 Cancer Res. pmid:12615702
Hamzei M et al. Osteoclast stimulating and differentiating factors in human cholesteatoma. 2003 Laryngoscope pmid:12616193
Siggelkow H et al. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. 2003 J. Bone Miner. Res. pmid:12619938
Wiethe C et al. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. 2003 J. Immunol. pmid:12626542
Ueland T et al. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. 2003 J. Clin. Endocrinol. Metab. pmid:12629078
Schoppet M et al. Increased osteoprotegerin serum levels in men with coronary artery disease. 2003 J. Clin. Endocrinol. Metab. pmid:12629080
Han W et al. Construction of a new tumour necrosis factor fusion-protein expression vector for high-level expression of heterologous genes in Escherichia coli. 2003 Biotechnol. Appl. Biochem. pmid:12630898
Koshihara Y et al. Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. 2003 J. Endocrinol. pmid:12630919
Alvarez L et al. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. 2003 Arthritis Rheum. pmid:12632438
Bord S et al. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. 2003 Bone pmid:12633785
Smith MD et al. Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. 2003 Ann. Rheum. Dis. pmid:12634226

Table of Content